Abstract
Introduction
Mycophenolate (MPA) is an antiproliferative agent that acts by uncompetitive, reversible and selective inhibition of type II inosine monophosphate dehydrogenase (IMPDH II), a key enzyme in the biosynthesis of purines ( ). MPA is metabolized by de novo 1 combined with sirolimus, the EMIT kit gave a significant but lesser overestimation of 18.7 26.8 as compared to LC-MS/MS, also with ± % variations depending on post-transplantation periods ( ). Therefore HPLC-UV and LC-MS/MS have so far been the standard 12 technologies used for MMF therapeutic drug monitoring. Roche Diagnostics designed and recently released a new MPA assay based on the enzymatic activity of recombinant IMPDH (the pharmacological target of MPA), the Roche (called herein Mycophenolic Acid assay ™ enzymatic MPA assay ), which was recently shown to precisely measure total MPA plasma levels in the range of 0.31 to 15 mg/l with ' ' excellent correlation with HPLC and LC-MS/MS methods and only 5 cross-reactivity with AcMPAG, though it tended to overestimate % MPA concentrations near the quantification limit ( ). 13
A multi-centre, randomized, prospective trial in 137 renal transplant recipients showed that MMF dose adjustment based on de novo MPA AUC resulted in significantly less rejections in the first year post-transplantation ( ). This clinical trial was conducted using 0 12h -14 pharmacokinetic models and Bayesian estimators specifically set up for plasma MPA levels as determined using HPLC ( , ), which 15 16
are now available on the ISBA (ImmunoSuppressants Bayesian Adjustment) website (at ) ( ). https://pharmaco.chu-limoges.fr/abis.htm 17
The larger, comparative, randomized FDCC trial did not show significant differences between the concentration-controlled and the fixe-dose arms, but the renal transplant patients were much more diverse (adults and pediatrics, on cyclosporine or tacrolimus, with MPA measurements made by HPLC or EMIT) and the tools used for dose adjustment (i.e., multilinear regression equations) were probably not as robust and accurate as Bayesian estimation ( ). On top of that, physician s compliance with dose adjustment proposals was only 52 18 
Material & methods

Patients and samples
Plasma samples were collected from 64 patients who gave their informed consent to participate in one of various pharmacokinetic studies approved by regional ethic committees and authorized by the Agence Fran aise de S curit Sanitaire des Produits de Sant , the
French Drug Agency. Sampling times ranged from pre-dose to 6 12 h post-dose, at post-transplant periods varying from day 7 to several -years. Twenty profiles came from 20 pediatric renal transplant recipients on cyclosporine (beyond one year post-transplantation), 16
profiles from 10 adult renal transplants on cyclosporine (10 early, i.e. within the first three months post-transplant, and 6 late or stable --periods), 30 profiles from 10 adult renal transplants on tacrolimus (collected at D7, M1 and M3), 28 profiles from 14 adult renal transplants on sirolimus (stable post-transplant periods) and 14 profiles from 10 adult lung transplants on tacrolimus (early and stable post-transplant periods).
All samples were kept frozen for a period of time ranging from 2 months to 2 years before the comparison study.
Analytical methods
The enzymatic MPA assay, based on a two-reagent system, was run on a COBAS INTEGRA 400 system. After sample addition to the reaction mixture, MPA in the sample inhibits IMPDH II that normally catalyzes the conversion of IMP (inosine monophosphate) and NAD (nicotinamide adenine dinucleotide) to XMP (xanthosine monophosphate) and NADH. The enzymatic reaction is monitored by measuring the rate of NADH formation at 340 nm ( ). MPA concentration is inversely proportional to the rate of NADH formation. The measuring 13 range used in this study was 0.4 to 15 mg/L. Using control samples for total MPA at three levels (0.8, 3.5 and 12 mg/L), the intra-assay CV was 1.0 , 0.6 and 1.1 , respectively (n 21).
The LC-MS/MS technique employed was previously described in detail ( ). Briefly, to 100 L of plasma were added 50 L of 11 between-day precision (CV < 10 and < 15 , respectively) and accuracy (mean bias < 7 for both) were satisfactory over the % % % % calibration range. Samples with MPA concentration > 30 mg/L (upper limit of quantitation) were diluted 1/2 with blank human plasma and re-analyzed.
Method comparison
The three QC samples provided by Roche Diagnostics for the enzymatic MPA assay and two commercial QC samples for MPA monitoring (ChromSystems, level I: 1.8 mg/L; and level II: 4.86 mg/L) were analyzed with each batch of patients samples using both For each PK profile, the two PK models (i.e., the two-compartment model with one gamma law and the one-compartment model with two gamma laws) were applied and the best one was selected based on the lowest Akaike criterion ( ), calculated as follows: 19 where is the value of the objective function at minimum and p the number of parameters in the model. being the main index targeted). Then, for practical reasons, a common LSS over the 3 periods was sought and evaluated. The whole procedure was repeated for MPA PK profiles generated using the enzymatic MPA assay and LC-MS/MS.
The influence of age, transplanted organ, associated drug and post-transplantation period on the relative differences between the two techniques was tested using one-way ANOVA, then two-by-two comparisons for the influence of the associated immunosuppressive drug by the Scheffe test. 4 10 Finally, the PK parameters obtained with the enzymatic MPA assay and LC-MS/MS at different post-transplantation periods on the one hand, and the respective Bayesian AUC estimates on the other hand were compared using paired t-tests. 
Results
The cross-checking of internal quality control samples analyzed routinely with the batches of patients samples showed that there was table III within the linearity range of the enzymatic MPA assay (0.4 to 15 mg/L), in order to avoid sample dilution as a confusing factor. They showed that the agreement between the two methods was excellent in all cases, with slightly though significantly higher overestimation of the enzymatic MPA assay in adults than in children, in patients on cyclosporine than in those on tacrolimus or sirolimus, and in the stable than in the early (i.e., within the first three months) post-transplantation periods ( ). In contrast, there was no significant difference  table III between lung-and kidney transplant recipients.
In the study database, 68 PK profiles containing at least 10 concentration-time points could be used to develop PK models and 
Discussion
The new enzymatic MPA assay tested showed excellent correlation with LC-MS/MS for the determination of total MPA in plasma of adult or pediatric, renal or lung transplant patients under cyclosporine, tacrolimus or sirolimus in the early or stable post-transplantation periods. A negligible systematic bias of about 6 was found between the two techniques when analysing spiked plasma samples + % routinely, with the enzymatic MPA assay showing better precision.
Full PK profiles may result in very low (down to 0.017 mg/L) to quite high (up to 33.4 mg/L) plasma levels, some of which were out of the analytical range of the enzymatic MPA assay. However, very low concentrations were mainly found for trough levels obtained very early after transplantation, when it is now widely accepted that trough levels have limited significance, at least for MMF dose adjustment (
). In the present as well as in previous studies ( , , ), we proposed Bayesian estimators of MPA AUC based on plasma 10 14 16 17 0 12h
samples collected at approx. 20 min, 1h and 3h post-dose, times at which MPA plasma levels were almost always above the LLOQ of the enzymatic MPA assay in our hands (0.4 mg/L). Above this LLOQ, the enzymatic MPA assay gave results very close to those of LC-MS/MS in all patients groups as determined by age, transplanted organ, co-administered immunosuppressant and post-transplantation period, though with slight overestimation of MPA plasma levels in patients on cyclosporine (mean 10.7 ). This last finding is in % agreement with those of previous reports comparing EMIT to LC-MS/MS, which showed that EMIT overestimated MPA plasma levels more in patients co-administered cyclosporine ( ) than sirolimus ( ) or tacrolimus ( , ), although overestimation was then globally 11 12 23 24 much higher with EMIT than with the enzymatic MPA assay herein. This might be due to the inhibition of the biliary excretion of MPA phase II metabolites, by cyclosporine but not tacrolimus or sirolimus ( ), resulting in an increase in plasma concentrations of these 25 -27 metabolites, mainly AcMPAG. However, it was shown that MPAG did not inhibit IMPDH, while MPA-acyl-glucuronide (AcMPAG) exhibited only 5 of MPA inhibition activity on the recombinant enzyme when incubated alone ( ), and even less when co-incubated
with MPA ( ). However, the overestimation of actual MPA levels by the enzymatic MPA assay found in patients on cyclosporine should 28 be of little clinical significance, so much so that this overestimation is proportional across the linearity range and with time post-dose, contrary to that of EMIT ( ). It should also be noted that a previously published inter-laboratory validation of the enzymatic MPA assay, 11
which was conducted after the present study and in which we also participated, found no significant overestimation, whether in patients on cyclosporine or on tacrolimus ( ). This could be due to the nature of the kit itself, as the beta-version used in the present study was 13 slightly different from the commercial version employed in the interlaboratory validation study.
Two different PK models with either one or two gamma laws, previously developed for renal transplant patients ( ) were used to fit 15 the present database. As raw data showed that patients could exhibit PK profiles with either one or two peaks, the best model was selected for each profile based on the Akaike criterion (a selection procedure now automatically applied to all three-point profiles sent to the ISBA website).
Significant differences in the PK parameters were found between LC-MS/MS and the enzymatic MPA assay, highlighting that analytical techniques not only impact the actual levels measured and the residual error of the models, but also the distribution of PK parameters in the population. This advocates the need for specific (or possibly adapted) models for pharmacokinetically-guided TDM when different analytical techniques are employed, even when they give close results as in the present study.
Bayesian estimators derived from these models were able to accurately estimate MPA AUCs when measured with the enzymatic MPA assay (i.e., more than 80 of the AUC estimates were within 20 of the actual values), with similar efficiency at all post-transplantation % ± % periods and for all three associated immunosuppressive drugs. When comparing Bayesian AUC estimates to those obtained with LC-MS/MS, significant although limited mean differences were observed, mainly in patients on cyclosporine or sirolimus. Also, the distribution of the AUC relative differences with respect to LC-MS/MS ( ) was very similar to that of the raw concentration data ( figure 4 ). This should not be of clinical significance, in as much as the commercial enzymatic MPA assay apparently presents less figure 1 overestimation than the beta version used in the present study (see above). This should not affect the accuracy of the Bayesian estimators developed here, which are more sensitive to curve shapes (hence PK parameters) than to absolute concentration values.
These tools were added to the ISBA website (https://pharmaco.chu-limoges.fr/abis.htm) to allow dose adjustment of MMF when measured using the Roche Diagnostics total MPA kit and have been used successfully since.
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